Well, the original question (if you follow the entire thread.. I'm just going to repost because nobody is doing much of anything except responding to single posts out of context):

Quote:

---

Just a random thought that came up. From what I know childhood cancers tends to be more aggressive and progress more rapidly than adult cancers. Could that mean that kids express the CCR5 receptor more than adults do? If so.. most likely kids will respond even better to Leronlimab compared to adults.

Read More: https://investorshangout.com/post/view?id=576...z6MX58jgc7

---

This was my response:

Quote:

---

I'd think if there was more CCR5 expression in kids, they'd be hit harder by CV... the Kawasaki-like syndrome is serious, not downplaying that, but they don't seem to have cardiac, pulmonary, and clotting issues. (Those may have more to do with ACE2). Leaky blood vessels and inflammation seem to be how younger people present.

Read More: https://investorshangout.com/post/view?id=576...z6MX5XS5HR

---

Which is the point of the original hypothesis... epigenetics of juvenile / adult expression of CCR5 as it pertains to CV infection and treatment.

"The kid dies, it doesn't matter how" is pretty much the antithesis of scientific inquiry... I'm not sure what your point is, either. I think there's a decent chance Leronlimab will have a similar, positive impact on juvenile COVID patients as well, but the fact they are presenting so differently from adult cases could have a significant effect on whether that turns out to be the case or not.